Navigation Links
Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA
Date:4/16/2009

NEW HAVEN, Conn., April 16 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (laromustine) Injection has been accepted for review by the U.S. Food and Drug Administration (FDA).

The Company had previously announced the filing of the NDA with the FDA in February 2009. The NDA presents data for Onrigin as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman, Chief Executive Officer, commented, "Acceptance of our NDA filing for review is an important milestone for Vion. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin in its first indication in the United States."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Application for Onrigin for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection (formerly Cloretazine (VNP40101M)), delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible rejection by the FDA of our request for priority review, and possible delays in the FDA's review process beyond our expectation for approval in the second half of 2009, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2008, and "Risk Factors" in Vion's Post-Effective Amendments on Form S-1 Registration Statement filed on March 23, 2009. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    COMPANY CONTACT:     Vion Pharmaceuticals, Inc.
                         Alan Kessman, Chief Executive Officer
                         Howard B. Johnson, President & CFO
                         (203) 498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Generic Pharmaceuticals Offer Exciting Growth Opportunities in Tanzania, Reveals Frost & Sullivan
2. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
3. Amylin Pharmaceuticals to Webcast First Quarter Results
4. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. Sigma-Tau Pharmaceuticals and Danisco BioActives Announce Partnership Agreement to Develop Drug Candidate for Prevention of Necrotizing Enterocolitis
7. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
8. Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
9. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
10. Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals
11. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot Company ... The goal is to ignite conversation via social media and word-of-mouth regarding vaginal ... has declared September “Humans with Vaginas” month, releasing a video celebrating the power ...
(Date:9/20/2017)... ... September 20, 2017 , ... Recognising that in today’s busy ... Greeny delivers positive results in just three weeks. Setting the groundwork for a ... Fitting seamlessly into hectic work and family schedules, participants can lose up to ...
(Date:9/20/2017)... York, NY (PRWEB) , ... September 20, 2017 ... ... , when asked at a gathering of executive marketers this week about the ... is prologue" , "Everything that has happened in business has brought us ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “Monique”: is ... uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned four ... then Crispi has been involved in real estate and cooking. , “The doctor’s ...
(Date:9/19/2017)... TX (PRWEB) , ... September 19, 2017 , ... Trusted ... settled over 175,000 debt accounts, translating to in excess of $835 million in resolved ... debt and other unsecured loans are some of the categories of debt settled by ...
Breaking Medicine News(10 mins):
(Date:8/28/2017)... 2017   Aesculight ®, a division of LightScalpel ®, LLC, ... Built on over 20 years of American veterinary laser surgery innovation, Aesculight® ... VetScalpel®Features and Enhancements ... excising a tumor with his new VetScalpel laser. Dr. Duclos practices veterinary ... ...
(Date:8/25/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a global ... management will be presenting a West business overview at three ... Management will present at the Baird 2017 Global Healthcare Conference, ... York, N.Y. , at 3:10 p.m. EDT on Wednesday, ... Westin Boston Waterfront in Boston, Mass. , ...
(Date:8/24/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is proud to announce ... USA (GDUSA) with three American Inhouse ... past four years. The competition recognizes outstanding creative ... publishing houses, nonprofit organizations, universities, and government agencies. ... in these categories: Posters ...
Breaking Medicine Technology: